Surgery for Patients With Spontaneous Deep Supratentorial Intracerebral Hemorrhage

A Retrospective Case-Control Study using Propensity Score Matching

Jun Zheng, MD, Hao Li, PhD, He-Xiang Zhao, MD, Rui Guo, MD, Sen Lin, PhD, Wei Dong, PhD, Lu Ma, PhD, Yuan Fang, PhD, Meng Tian, PhD, Ming Liu, PhD, and Chao You, MD

Abstract: Spontaneous intracerebral hemorrhage (sICH) is one of the most dangerous cerebrovascular diseases, especially when in deep brain. The treatment of spontaneous deep supratentorial intracerebral hemorrhage is still controversial. We conducted a retrospective case-control study using propensity score matching to compare the efficacy of surgery and conservative treatment for patients with deep supratentorial hemorrhage.

We observed the outcomes of consecutive patients with spontaneous deep supratentorial hemorrhage retrospectively from December 2008 to July 2013. Clinical outcomes of surgery and conservative treatments were compared in patients with deep sICH using propensity score matching method. The primary outcome was neurological function status at 6 months post ictus. The second outcomes included mortality at 30 days and 6 months, and the incidence of complications. Subgroup analyses of 6-month outcome were conducted.

Sixty-three (22.6%) of the 278 patients who received surgery had a favorable neurological function status at 6 months, whereas in the conservative group, 66 of 278 (23.7%) had the same result (P = 0.763). The 30-day mortality in the surgical group was 19.06%, whereas 30.58% in the conservative group (P = 0.002). There was significant difference in the mortality at 6 months after ictus as well (23.38% vs 36.33%, P = 0.001). The subgroup analyses showed significantly better outcomes for the surgical group when hematoma was >40 mL (13.33% vs 0%, P = 0.005) or complicated with intraventricular hemorrhage (16.77% vs 7.27%, P = 0.034). For complications, the risk of pulmonary infection, gastrointestinal hemorrhage, urinary infection, pulmonary embolus, and need for tracheostomy/long term ventilation in the surgical group was higher than the conservative group (31.29% vs 15.47%, P < 0.001; 6.83% vs 3.96%, P = 0.133; 2.88% vs 1.80%, P = 0.400; 1.80% vs 1.08%, P = 0.047; 32.73% vs 23.38%, P = 0.014).

Surgery could reduce the short-term mortality as well as long-term mortality in patients with spontaneous deep supratentorial hemorrhage. Moreover, surgery might improve the functional outcome in patients with large hematoma or with IVH compared with conservative treatment. Surgery might be a beneficial choice for part of the patients with spontaneous deep supratentorial hemorrhage, but further detailed research is still needed.

INTRODUCTION

It is reported that over 1 million people suffer from spontaneous intracerebral hemorrhage (sICH) every year worldwide.1,2 The 30-day mortality is about 30% to 55%. The majority of the survivors live with serious neurological sequelae that require long-term medical and social care.3-4 Only 12% to 39% of the survivors have favorable neurological functions recovered.4,5 Most sICHs happen in the deep area of brain such as basal ganglia and thalamus.6 Some studies showed that prognosis of sICH was related to the depth of the hematoma. Patients with deep sICH showed poor outcome compared to those with superficial lobar hemorrhage.7,8

The treatment of sICH is still debatable among the surgeons up to now. The focus of the controversy is whether evacuation of hematoma will be able to improve the prognosis. Some clinical and experimental evidence showed that the removal of hematoma might reduce nervous tissue damage, possibly by relieving local ischemia and removing noxious chemicals.9-11 Nevertheless, deep hematoma is inaccessible and the surgical approach paths might interfere with the cerebral functional areas. Therefore, most neurologists are more likely to adopt conservative treatment rather than surgically removing the deep hematoma. Nonetheless, for patients with large hematoma and rapid neurological deterioration, surgery might be a better choice.12

Several studies aiming to explore the efficacy of surgery for patients with sICH have been carried out. However, the results were inconclusive. The first prospective randomized controlled trial was reported by Mekissock et al13 in 1961, which came to the conclusion that the patients received surgery had a worse outcome than the patients receiving conservative treatment. Another influential prospective study is the STICH
significant better than conservative treatment in some sub-
mortality, 6-month mortality, and complications. Other analysis included 30-day
the hematoma was located in basal ganglia or thalamus; hematoma was ≥1 cm in depth from the cortex surface of the brain; the volume of hematoma was ≥ 20 mL. Patients were excluded if: hematoma was caused by secondary factors (intra cranial tumor, arteriovenous malformation or aneurysm); contraindications of surgery existed; hematoma affected the brain stem; known advanced dementia or disability existed before ICH happened. In the present study, the contraindications of surgery were listed as followed: with coagulation disorders or history of anticoagulant medications; with severe hepatic and renal dysfunction; with terminal brain hernia (bilateral pupils dilated and central respiratory failure). Patients with uncompleted data were also excluded. Hematoma volume was calculated from CT scans using the formula A × B × C/2, where A is the greatest diameter on the largest hemorrhage slice, B is the maximal diameter perpendicular to A, and C is the vertical hematoma depth.18 The patients were all followed up for over 6 months.

Treatment

All patients were managed in the stroke unit with standard medical treatment and care. CT scans, blood routine, biochemical examinations (eg, hepatic and renal function, electrolytes), and routine coagulation studies were performed immediately when the patients were admitted to the emergency department. The medical history and neurologic physical examination were also recorded immediately after hospitalized into the stroke unit. All patients had their vital signs monitored and were given supportive treatment at the same time.

Surgery

All the surgeries were conducted by a special sICH treatment team, which was consisted by well-trained neurosurgeons. All the patients received hematoma evacuation. The techniques used were craniotomy or neuroendoscopy. Decompressive craniotomy was conducted if necessary. In some conditions, an extraventricular drainage was conducted before or after the operation. The surgical method was decided by the surgeons preoperatively. All the craniotomy hematoma evacuation was assisted by operative microscope and followed the principle of minimally invasiveness.

Medical Treatments

All the patients received standard medical treatments of sICH. The medical treatments included decreasing intracranial pressure, blood pressure control, prevention of complications, and other treatments individually. The mannitol or glycerin fructose was administered with appropriate dose based on the clinical conditions of patients. All the medical managements followed the recommendations of AHA/ASA guidelines and clinical experience.19,20

Outcomes and Data Collection

Patients were followed up for at least 6 months. The primary outcomes assessed were neurological functional status of survivors at 6 months post ictus. The secondary outcomes included: mortality at 30 days, mortality at 6 months post ictus, and complications. The neurological functional status was evaluated by using the Modified Rankin Scale (mRS). Complications including pulmonary infection, gastrointestinal bleeding, urinary tract infection, pulmonary embolus, and need for tracheostomy/long-term mechanical ventilation were also collected.

Statistical Analysis

Given the selection bias inherent to retrospective observational studies, a one-to-one matching analysis was performed between the surgical group and conservative group on the basis of the estimated propensity scores of each patient in the present study.21 To estimate the propensity score, a function was built by logistic regression model for the receipt of surgery on the basis of patients’ clinical factors. The clinical factors included age, admission Glasgow coma scale (GCS), location of hematoma, midline shift (MS), volume of hematoma, depth of hematoma, and medical histories. Cases in the 2 groups were matched according to the similarity of their propensity score noreplacemently by the method of nearest-neighbor matching. The 6-month mRS was dichotomized as poor outcome (mRS 3–6) and favorable outcome (mRS 0–2). Primary analysis was to compare 6-month neurological functional outcomes post ictus between the surgical group and conservative group. A further subgroup analysis of 6-month outcome was stratified by age, Glasgow coma scale (GCS), location of hematoma, hematoma volume, midline shift (MS), and with/without intraventricular hemorrhage (IVH). Other analysis included 30-day mortality, 6-month mortality, and complications.

Statistically significance was assumed with a probability value of <0.05. Chi-square test was used for analyzing the categorical value. Continuous variable data were expressed as the means ± standard deviations (SD) and analyzed by t test.

RESULT

From December 2008 to July 2013, a total of 856 patients meet the inclusion criteria. In the 824 patients, 79 patients were
lost to follow-up and 26 patients have uncompleted data. A total of 719 patients were included in the present study, of whom 278 patients underwent surgery. Patients’ baseline characteristics at the time of hospitalization are listed in Table 1. There are significant differences between the 2 groups in age, history of smoke, alcohol consumption, location of hematoma, and depth of hematoma. After propensity score matching, the baselines were well matched. In the matched cases, the range of age was between 22 and 90 years (mean 54.55 \pm 12.01 years). A total of 512 (92.09%) patients were hospitalized in 24 h after ictus and the rest of the patients 72 h. Two hundred twenty-four (40.29%) patients had a GCS of 3–8 and only 146 (26.26%) showed better outcome from surgery than conservative treatment. Significant differences were observed between the 2 groups in 30-day mortality ($P = 0.001$) after ictus. At 6 months after ictus, conservative group were more likely to develop a fatal central respiratory-circulatory failure (65.35% vs 52.31%, $P = 0.094$). In contrast, patients who received surgery were more likely to die of complications (38.46% vs 26.73%, $P = 0.112$). As for complications, the risk of pulmonary infection and need for tracheostomy/long-term mechanical ventilation in the surgical group was higher than that in the conservative group (31.29% vs 15.47%, $P < 0.001$; 32.73% vs 23.38%, $P = 0.014$). The incidences of gastrointestinal hemorrhage, urinary tract infection, and pulmonary embolus in the surgical group were higher compared with conservative group as well, without statistical difference (6.83% vs 3.96%, $P = 0.476$). Subgroup analyses of 6-month functional outcome were listed in Table 3. Of all the subgroup analyses, 2 showed heterogeneity. Patients with hematoma >40 mL were more likely to have a favorable outcome in surgical group than in the conservative group (13.33% vs 0%, $P = 0.005$). Another factor was IVH. Patients with IVH showed better outcome from surgery than conservative treatment (16.67% vs 7.27%, $P = 0.034$).

### Table 1. Baseline of the Patients Before and After Propensity Score Matching

|                          | Surgical Group (n = 278) | Conservative Group (n = 441) | $P$  |
|--------------------------|--------------------------|-----------------------------|------|
| Male                     | 184                      | 316                         | 0.121|
| Age, y                   | 54.23 ± 11.62            | 58.49 ± 13.28               | 0.000|
| Time ictus, h            | 11.78 ± 13.51            | 11.05 ± 12.07               | 0.447|
| GCS                      |                          |                             | 0.111|
| 3–8                      | 113                      | 197                         |      |
| 9–12                     | 93                       | 159                         | 0.588|
| 13–15                    | 72                       | 85                          |      |
| Paralyzed                | 230                      | 364                         | 0.947|
| Dysphasic or aphasis     | 135                      | 231                         | 0.318|
| History                  |                          |                             |      |
| Hypertension             | 150                      | 229                         | 0.596|
| Diabetes mellitus        | 15                       | 16                          | 0.256|
| Previous stroke          | 7                        | 14                          | 0.611|
| Smoker                   | 74                       | 97                          | 0.102|
| Alcohol                  | 75                       | 81                          | 0.006|
| Location of hematoma     |                          |                             | 0.019|
| Basal ganglia            | 231                      | 330                         |      |
| Thalamus                 | 32                       | 85                          |      |
| Both                     | 15                       | 26                          |      |
| Volume of hematoma, mL   | 35.25 ± 15.59            | 35.42 ± 21.10               | 0.910|
| Depth of hematoma, cm    | 1.59 ± 0.32              | 1.66 ± 0.32                 | 0.002|
| MS, mm                   | 6.86 ± 3.45              | 6.71 ± 4.81                 | 0.659|
| With IVH                 | 102                      | 187                         | 0.128|

GC = Glasgow coma scale, IVH = intraventricular hemorrhage, MS = midline shift.

*Data are mean ± SD or number of patients.

Surgery for Deep Intracerebral Hemorrhage
DISCUSSION

From the present study, we found that surgery could reduce the short-term and long-term mortality in patients with spontaneous deep supratentorial hemorrhage. The long-term functional outcomes were similar between the 2 groups. However, patients who received surgery might have a better outcome in certain conditions: volume of hematoma >40 mL, and patient with concurrent IVH.

So far, a total of 13 randomized clinical trials comparing surgery and conservative treatment for patients with sICH have been published, 8 of which provided data of deep brain hemorrhage (Table 4).7,14–16,22–29 Among these trials, the largest one is the STICH trial.7 The STICH is an international multicenter prospective randomized clinical trial, which included 1033 patients from 27 countries from 1998 to 2003, among whom 442 patients diagnosed with deep supratentorial hemorrhage were analyzed in the subgroup analysis. In these 442 patients, 208 patients underwent early surgical treatment, and the rest 234 patients received initial conservative treatment. Favorable outcomes at 6 months did not significantly differ between the 2 groups. Another 4 previously published studies got a similar outcome that patients with hematoma located in the basal ganglia or thalamus did not benefit from hematoma evacuation.22,24–26 However, a study published by Pantazis et al14 in 2006 had a different result. A total of 108 patients with sICH were enrolled in this study from 1998 to 2003. Among them, 57 patients with hematoma in putamen were analyzed in the subgroup. The result showed that patients who underwent craniotomy had a better functional outcome than those received conservative treatment. Like most previous studies, result of the present study showed a poor outcome in patients with deep supratentorial hemorrhage. Besides, surgery did not improve the long-term outcome compared with conservative treatment. Most neurosurgeons attributed such result to the additional surgical traumatization. To reduce surgical traumatization, some minimal invasive techniques were adopted in hematoma evacuation. Though the long-term follow-up of some prospective randomized controlled trials showed that patients with deep hematoma might benefit from minimally invasive surgery, these kind of procedures still had some limitations including higher risk of rehemorrhage and intracranial infection.31

In the present study, we found that patients with volume of hematoma >40 mL were more likely to have a favorable outcome from surgery. In patients with sICH, volume of hematoma is one of the most important parameter to evaluate the severity of the condition. Patients with larger hematoma always have a higher intracranial pressure (ICP) and severer neurological functional damage. Early evacuation of hematoma might protect brain tissue from the ischemia caused by the elevated ICP and reduce the noxious chemicals generated from hematoma. Our result differs from most previous studies in which patients enrolled were complicated with lobar hematoma. The different patient populations might cause the difference between our results and the previous ones.

Previous study showed that the sICH patients with IVH were more likely to have a poor outcome in previous studies.32 Mainstream views attribute this to 4 pathophysiological mechanisms: the mass effect of the hematoma, toxicity of blood-breaking products, acute obstructive hydrocephalus, and chronic hydrocephalus.33 In the present study, patients with deep supratentorial hemorrhage with IVH had a poor prognosis likewise. However, patients with IVH who received surgery were more likely to get a favorable outcome. By contrast, the STICH II study showed that surgery could have survival advantage for patients with superficial hematoma without IVH.8 Such difference might be caused by different locations of the primary hemorrhage. Generally, for patients with deep hematoma and IVH, we evacuated part of the hematoma in the ventricle with the aid of operative microscope, and placed the drainage tube in the fistula of ventricle. In some cases of...
TABLE 3. Subgroup Analysis of 6-month Functional Outcome

|                  | Surgical Group (n/N) | Conservative Group (n/N) | P   |
|------------------|----------------------|--------------------------|-----|
| **Age, y**       |                      |                          |     |
| ≤65              | 55/230               | 57/228                   | 0.787|
| >65              | 8/48                 | 9/50                     | 0.862|
| **GCS**          |                      |                          |     |
| 3–8              | 15/113               | 8/111                    | 0.135|
| 9–12             | 28/93                | 35/93                    | 0.278|
| 13–15            | 20/72                | 23/74                    | 0.662|
| **Location of hematoma** |                  |                          |     |
| Basal ganglia    | 60/231               | 62/236                   | 0.942|
| Thalamus         | 3/32                 | 4/26                     | 0.769|
| Both             | 0/15                 | 0/16                     | /    |
| **Volume of hematoma, mL** |              |                          |     |
| ≤40              | 53/203               | 66/221                   | 0.390|
| >40              | 10/75                | 0/57                     | 0.005|
| **MS**           |                      |                          |     |
| MS ≤5 mm        | 26/87                | 46/107                   | 0.060|
| 5 mm < MS ≤10 mm| 31/140               | 14/110                   | 0.054|
| MS >10 mm       | 6/51                 | 6/61                     | 0.742|
| **IVH**          |                      |                          |     |
| With IVH         | 17/102               | 8/110                    | 0.034|
| Without IVH     | 46/176               | 58/168                   | 0.090|

GCS = Glasgow coma scale, IVH = intraventricular hemorrhage, MS = midline shift.

TABLE 4. Summary of Previous Randomized Controlled Trials Enrolled Patients With Deep Supratentorial Hemorrhage During the CT Era

| Author (Publish Time) | Surgery Methods | Study Population* | Subgroup Analyse<sup>+</sup> |
|-----------------------|-----------------|-------------------|-------------------------------|
|                       |                 |                   | Surgery<sup>†</sup> | Conservative Treatment<sup>†</sup> | Odds Ratio (95% CI)<sup>†</sup> |
| Auer et al<sup>22</sup> | Edoscopy        | 40 putaminal      | 23/26                        | 29/29                           | 0.11 (0.01, 2.31)               |
|                       |                 | 15 thalamic       |                              |                                |                                 |
|                       |                 | 30 basal ganglia  |                              |                                |                                 |
|                       |                 | 5 thalamic        |                              |                                |                                 |
| Juvela et al<sup>23</sup> | Craniotomy     | 30 basal ganglia  | Not mentioned                |                                |                                 |
|                       |                 | 21 putaminal      |                              |                                |                                 |
| Batjer et al<sup>24</sup> | Craniotomy     | 70 putaminal/or basal ganglia | 37/55               | 27/56                           | 2.21 (1.02, 4.77)               |
|                       |                 | 14 thalamic       |                              |                                |                                 |
|                       |                 | 27 putaminal and thalamic |                |                                |                                 |
| Chen et al<sup>25</sup> | Craniotomy     | 74 external capsule or putaminal | 9/15               | 11/16                           | 0.68 (0.16, 2.99)               |
|                       |                 | 3 Thalamic        |                              |                                |                                 |
|                       |                 | 358 internal capsule or thalamic |                |                                |                                 |
| Morgenstern et al<sup>26</sup> | Craniotomy   | 31 Putaminal       | 9/15                         | 11/16                           | 0.68 (0.16, 2.99)               |
|                       |                 | 7 Putaminal/or basal ganglia |                |                                |                                 |
| Zuccarello et al<sup>27</sup> | Stereotax      | 74 external capsule or putaminal | 9/15               | 11/16                           | 0.68 (0.16, 2.99)               |
|                       |                 | 3 Thalamic        |                              |                                |                                 |
| Chen et al<sup>28</sup> | Craniotomy     | 74 external capsule or putaminal | 9/15               | 11/16                           | 0.68 (0.16, 2.99)               |
|                       |                 | 358 internal capsule or thalamic |                |                                |                                 |
| Zhou et al<sup>29</sup> | Stereotax      | 186 basal ganglia  | Not mentioned                |                                |                                 |
|                       |                 | 22 thalamus       |                              |                                |                                 |
| Teernstra et al<sup>30</sup> | Stereotax    | 33 deep-seated    | Not mentioned                |                                |                                 |
| Hattori et al<sup>15</sup> | Stereotax      | 242 putaminal      | 60/121                       | 82/121                          | 0.47 (0.28, 0.79)               |
| Mendelow et al<sup>7</sup> | Craniotomy     | 442 deep-seated   | 174/208                      | 184/234                         | 1.39 (0.86, 2.25)               |
|                       |                 | 174/208           | 184/234                      |                                |                                 |
| Pantazis et al<sup>14</sup> | Craniotomy   | 57 putaminal       | 22/29                        | 28/28                           | 0.05 (0.00, 0.97)               |
| Wang et al<sup>16</sup>  | Stereotax       | 377 basal ganglia  | 174/297                      | 178/286                         | 0.70 (0.50, 0.99)               |

CI = confidence interval, CT = computed tomography.
<sup>†</sup>Data were only from the patients with hematoma located in the deep area of brain.
<sup>†</sup>Data are number of unfavorable outcome/number of patients randomized to the group.
<sup>†</sup>The OR are calculated to compare the outcomes of surgery and conservative treatment.
thalamus hemorrhage with IVH, an external ventricular drainage was placed before or after craniotomy hematoma evacuation. These measures could not only reduce the mass effect of hematoma, but also lower the risk of acute hydrocephalus. This might be the reason that sICH patients with IVH had a better outcome in surgical group.

The mortality is a hot subject of debate in the present study. Increased ICP will lead to hernia, which is the main cause of death in patients with sICH. Patients with serious deep intracerebral hemorrhage usually die from central respiratory-circulatory failure caused by herniation in the acute phase. Early hematoma evacuation could reduce ICP and help patients with sICH go through the acute phase. In our opinion, ICP is one of the most important parameters to evaluate in the surgical decision making process. A recent study showed that decompressive craniotomy (DC) might be useful to decrease the ICP and improve the prognosis in patients with large basal ganglia hemorrhage. Our finding is similar to the guideline. The last edition of AHA/ASA guideline hold the opinion that DC with or without hematoma evacuation might reduce mortality for patients with supratentorial ICH who are in a coma, have large hematomas with significant midline shift, or have elevated ICP refractory to medical management.

We must admit that the present study had some limitations. First, the present study was a single-center retrospective case-controlled study using propensity score matching. Potential selective bias still existed though greatly reduced. The sample size of the present study was not large enough to provide robust evidence for clinical practice. Second, even though most of the patients received surgery within 8 hours post ictus in the present study, some of the patients underwent surgery after 24 hours post ictus, which might affect the efficacy of surgery. The reason why we did not discuss the time of surgery was that there was a large span of time from onset to surgery in the present study. Third, we only used a radiographic index, the MS, to evaluate the preoperational ICP. There are some other radiographic indexes such as changes of ventricle to evaluate the ICP. Using a CT score calculating from both the MS and changes of ventricle to evaluate preoperational ICP might be preferable. To further investigate this topic, some high quality, rigorous, randomized controlled trials are needed.

CONCLUSION

The treatment of patients with spontaneous deep supratentorial hemorrhage had puzzled the neurosurgeons for quite a long time. Though many studies had been carried out, there is still no sufficient evidence to justify whether a patient with spontaneous deep supratentorial hematoma should be treated surgically. The present study showed that surgery could reduce the short-term and long-term mortality in patients with spontaneous deep supratentorial hemorrhage. Moreover, surgery might improve the functional outcome in patients with large hematoma or with IVH compared with conservative treatment. The result of the present study might help the surgical decision making for patients with spontaneous deep supratentorial hemorrhage in the future. Surgery might be a beneficial choice for part of the patients with spontaneous deep supratentorial hemorrhage, but further detailed research is still needed.

REFERENCES

1. Liu M, Wu B, Wang WZ, et al. Stroke in china: epidemiology, prevention, and management strategies. Lancet Neurol. 2007;6:456–464.
2. Qureshi Al, Tuhrim S, Broderick JP, et al. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344:1450–1460.
3. Broderick JP, Brott T, Tomsick T, et al. Intracerebral hemorrhage more than twice as common as subarachnoid hemorrhage. J Neurosurg. 1993;78:188–191.
4. van Asch CJ, Luitsel MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: A systematic review and meta-analysis. Lancet Neurol. 2010;9:167–176.
5. Mayer SA, Rincon F. Treatment of intracerebral haemorrhage. Lancet Neurol. 2005;4:662–672.
6. Inagawa T, Ohbayashi N, Takechi A, et al. Primary intracerebral hemorrhage in izumo city, japan: Incidence rates and outcome in relation to the site of hemorrhage. Neurosurgery. 2003;53:1283–1297; discussion 1297–1288.
7. Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the international surgical trial in intracerebral haemorrhage (stich): A randomised trial. Lancet. 2005;365:387–397.
8. Mendelow AD, Gregson BA, Rowan EN, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (stich ii): A randomised trial. The Lancet. 2013;382:397–408.
9. Azarof I, Huang KT, Basu S, et al. Nitric oxide scavenging by red blood cells as a function of hematocrit and oxygenation. J Biol Chem. 2005;280:39024–39032.
10. Power C, Henry S, Del Bigio MR, et al. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol. 2003;53:731–742.
11. Qureshi Al, Ali Z, Suri MF, et al. Extracellular glutamate and other amino acids in experimental intracerebral hemorrhage: An in vivo microdialysis study. Crit Care Med. 2003;31:1482–1489.
12. Hemphill JC 3rd, Greenberg SM. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2015;46:2032–2060.
13. McKissock W, Richardson A, Taylor J. Primary intracerebral hemorrhage: a controlled trial of surgical and conservative treatment in 180 unselected cases. Lancet. 1961;278:221–226.
14. Pantazis G, Tsitopoulos P, Mihas C, et al. Early surgical treatment vs conservative management for spontaneous supratentorial intracerebral hematomas: a prospective randomized study. Surg Neurol. 2006;66:492–501; discussion 501–492.
15. Hattori N, Katayama Y, Maya Y, et al. Impact of stereotactic hematoma evacuation on activities of daily living during the chronic period following spontaneous putaminal hemorrhage: A randomized study. J Neurosurg. 2004;101:417–420.
16. Wang WZ, Jiang B, Liu HM, et al. Minimally invasive cranio puncture therapy vs. Conservative treatment for spontaneous intracerebral hemorrhage: Results from a randomized clinical trial in china. Int J Stroke. 2009;4:11–16.
17. Zhou X, Chen J, Li Q, et al. Minimally invasive surgery for spontaneous supratentorial intracerebral hemorrhage: A meta-analysis of randomized controlled trials. Stroke. 2012;43:2923–2930.
18. Kothari RU, Brott T, Broderick JP, et al. The abcs of measuring intracerebral hemorrhage volumes. Stroke. 1996;27:1304–1305.
19. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: A guideline from the american heart association/american stroke association stroke council, high blood pressure research council, and the quality of care and outcomes in research interdisciplinary working group. Circulation. 2007;116:e391–413.
20. Morgenstern LB, Hemphill JC 3rd, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2010;41:2108–2129.

21. Sascha OB, Andrea I. Estimation of average treatment effects based on propensity scores. *Stata J.* 2002;2:358–377.

22. Auer LM, Deinsberger W, Niederkorn K, et al. Endoscopic surgery versus medical treatment for spontaneous intracerebral hematoma: A randomized study. *J Neurosurg.* 1989;70:530–535.

23. Juvela S, Heiskanen O, Poranen A, et al. The treatment of spontaneous intracerebral hemorrhage. A prospective randomized trial of surgical and conservative treatment. *J Neurosurg.* 1989;70:755–758.

24. Batjer HH, Reisch JS, Allen BC, et al. Failure of surgery to improve outcome in hypertensive putaminal hemorrhage. A prospective randomized trial. *Arch Neurol.* 1990;47:1103–1106.

25. Chen XC, Yang HM, Chen ZP. A prospective randomized trial of surgical and conservative treatment of hypertensive intracerebral haemorrhage. *Acta Acad Shanghai Med.* 1992;19:237–240.

26. Morgenstern LB, Frankowski RF, Shedden P, et al. Surgical treatment for intracerebral hemorrhage (stich): A single-center, randomized clinical trial. *Neurology.* 1998;51:1359–1363.

27. Zuccarello M, Brott T, Derex L, et al. Early surgical treatment for supratentorial intracerebral hemorrhage: A randomized feasibility study. *Stroke.* 1999;30:1833–1839.

28. Chen XC, Wu JS, Zhou XP, et al. The randomized multicentric prospective controlled trial in the standardized treatment of therapeutic outcomes with conservative therapy. *Chin J Clin Neurosci.* 2001;9:365–368.

29. Zhou L, Pang L. Minimally invasive surgery for hypertensive hematomas—a prospective randomized multiple centers trial. *Chin J Clin Neurosci.* 2011;9:151–154.

30. Teernstra OP, Evers SM, Lodder J, et al. Stereotactic treatment of intracerebral hematoma by means of a plasminogen activator: A multicenter randomized controlled trial (sichpa). *Stroke.* 2003;34:968–974.

31. Cho DY, Chen CC, Chang CS, et al. Endoscopic surgery for spontaneous basal ganglia hemorrhage. Comparing endoscopic surgery, stereotactic aspiration, and craniotomy in noncomatose patients. *Surg Neurol.* 2006;65:547–555; discussion 555–546.

32. Hanley DF. Intraventricular hemorrhage. Severity factor and treatment target in spontaneous intracerebral hemorrhage. *Stroke.* 2009;40:1533–1538.

33. Gaberel T, Magheru C, Emery E. Management of non-traumatic intraventricular hemorrhage. *Neurosurg Rev.* 2012;35:485–495.

34. Li Q, Yang CH, Xu JG, et al. Surgical treatment for large spontaneous basal ganglia hemorrhage: Retrospective analysis of 253 cases. *Br J Neurosurg.* 2013;27:617–621.